Overview

The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.

Status:
RECRUITING
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
Despite the available means of treating primary arterial hypertension, the prevalence of hypertensive patients with inadequately controlled blood pressure levels, remains high. The identification of biomarkers with prognostic and predictive roles seems to play an important role in the management of hypertensive patients. Proteomic analysis studies provide encouraging results in the identification of such biomarkers. The goal of this clinical study is to is to highlight peptides through urinary proteomic analysis of obese hypertensive patients, capable of predicting blood pressure response, following treatment with irbesartan or eplerenone.
Phase:
NA
Details
Lead Sponsor:
Hippocration General Hospital
Collaborator:
National and Kapodistrian University of Athens
Treatments:
Eplerenone
Irbesartan